Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Recipients from living donors kidneys HLA-identical were lower risk for acute rejection,
graft loss or death. There is no clear definition of what is ideal immunosuppressive regimen
for this population.
Everolimus (EVR) was associated with lower incidence of viral infections and also the lowest
incidence of neoplasms. Furthermore, immunosuppressive regimens based everolimus allow the
reduction or elimination of calcineurin inhibitors reducing cardiovascular risks associated
with chronic use of these agents. Moreover, the use of EVR is associated with increased
incidence of proteinuria, which associated mechanism has not been fully elucidated. Knowing
that proteinuria may be the first indication of recurrence of the underlying renal disease,
detailed information about the patient's medical history and histological analysis of the
graft may contribute with additional knowledge in this area.
The aim of this prospective, open, single arm study that will be performed only in the
Hospital do Rim e Hipertensão, is investigating the outcomes of kidney transplantation in
recipients of HLA identical living donor, receiving an everolimus-based immunosuppressive
regimen. This will include 100 recipients of first or second kidney transplant from a living
donor HLA identical to the Kidney and Hypertension Hospital, which will be followed by a
period of 12 months.